Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: A randomized clinical trial using electronic monitoring

Canadian Journal of Cardiology

Volumn 13, Issue 10, 1997, Pages 914-920

  Leenen, F H H ^a   Wilson, T W ^b   Bolli, P ^b   Larochelle, P ^b   Myers, M ^b   Handa, S P ^b   Boileau, G ^b   Tanner, J ^b  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b NONE

Author keywords

Amlodipine; Calcium antagonists; Diltiazem; Drug treatment; Duration of action; Hypertension; Partial compliance

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; DILTIAZEM;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BORDERLINE HYPERTENSION; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EDEMA; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; CANADA; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PATIENT COMPLIANCE; PRIMARY HEALTH CARE;

EID: 0030815747     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Haynes RB. Introduction. In: Haynes RB, Taylor DW, Sackett DL, eds, Compliance in Health Care. Baltimore: Johns Hopkins University Press, 1979:1-7.
2. Sharkness CM, Snow DA. The patient's view of hypertension and compliance. Am J Prev Med 1992;8:141-6.
3. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1993;153:154-83.
4. Sackett DL. The hypertensive patient: 5. Compliance with therapy Can Med Assoc J 1979;121:259-61.
5. Guerero D, Rudd P, Bryant-Kosling C, Middleton BF. Antihypertensive medication-taking; investigation of a simple regimen. Am J Hypertens 1993;6:586-92.
6. Alderman MH, Davis TK. Hypertension control at the worksite. J Occup Med 1976; 18:793-6.
7. Logan AG. Role of paraprofessionals in improving compliance with antihypertensive treatment. J Hypertens 1985;3(Suppl 1):65-8.
8. Pullar T, Birtwell AJ, Wiles PG, Hay A, Feely MP. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin Pharmacol Ther 1988;44:540-5.
9. Logan AG, Irvine MJ. Compliance, labelling and hypertension. In: Swales JD, ed. Textbook of Hypertension. Oxford: Blackwell Scientific Publications, 1994:1267-82.
10. Cramer JA, Mattison RH, Prevey ML, Scheyer MDS, Ouellette RN. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;22:3273-7.
11. Baird MG, Bentley-Taylor MM, Carruthers SG, et al. A study of efficacy, tolerance and compliance of once-daily versus twice-daily metoprolol (Betaloc) in hypertension. Clin Invest Med 1984;7:95-102.
12. Eisen SA, Miller DM, Woodward RS, Spitznagel E, Przyeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-4.
13. Sramek JJ, Cutler NR, Seifert RD, Luna AD. Compliance in hypertension: daily v twice daily. Am J Hypertens 1993;6:1063.
14. Levy G. A pharmacokinetic perspective on medicament noncompliance. Clin Pharmacol Ther 1993;54:242-4.
15. Leenen FHH, Fourney A. Persistence of anti-hypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) versus short (diltiazem) elimination half-life. Br J Clin Pharmacol 1996;41:83-8.
16. Averbuch M, Weintraub M, Pollack DJ. Compliance assessment in clinical trials: the MEMS device. J Clin Res Pharmacoepidemiol 1990;4:199-204.
17. Waeber B, Erne P, Saxenhofer H, Heynen G. Use of drugs with more than a twenty-four hour duration of action. J Hypertens 1994;12(Suppl 8):S67-71.
18. Detry JMR, Block P, De Backer G, Degaute JP, Six R. Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. Eur J Clin Pharmacol 1995;47:477-81.
19. Sanson-Fisher RW, Clover K. Compliance in the treatment of hypertension; a need for action. Am J Hypertens 1995;8:82S-8S.
20. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984;6:592-9.
21. Haynes RB. A critical review of the 'determinants' of patient compliance with therapeutic regimens. In: Sackett DL, Haynes RS, eds. Compliance With Therapeutic Regimens. Baltimore: Johns Hopkins University Press, 1976:3.
22. Sackett DL, Gibson ES, Taylor DW, Haynes RB, Hackett BC, Roberts RS. Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet 1975;i:1205-7.
23. Rudd P, Byyny RL, Zachary V, et al. The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol Ther 1989;46:169-76.
24. Rand CS, Nides M, Cowles MK, Wise RA, Connett J. Long-term metered-dose inhaler adherence in a clinical trial. Am J Respir Crit Care Med 1995;152:580-8.